Tissue biomarkers in colon cancer (COC): The translational study on a phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II-III COC patients (PETACC 3-EORTC 40993-SAKK 60/00)

Roth, A; Tejpar, Sabine; Yan, P; Rocca, R; Hectors, Dietrich; Hsu Schmitz, S; Barone, C; Bodoky, G; Labianca, R; Cunningham, D; Van Cutsem, Eric; Bosman, F

doi:10.1016/S1359-6349(07)70941-2

Annals of oncology

Tissue biomarkers in colon cancer (COC): The translational study on a phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II-III COC patients (PETACC 3-EORTC 40993-SAKK 60/00)

Author:

Roth, A

Tejpar, Sabine ; Yan, P ; Rocca, R ; Hectors, Dietrich ; Hsu Schmitz, S ; Barone, C ; Bodoky, G ; Labianca, R ; Cunningham, D ; Van Cutsem, Eric ; Bosman, F

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3202 Clinical sciences, 3211 Oncology and carcinogenesis

Annals of oncology Tissue biomarkers in colon cancer (COC): The translational study on a phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II-III COC patients (PETACC 3-EORTC 40993-SAKK 60/00)

Author:

Keywords:

Annals of oncology

Tissue biomarkers in colon cancer (COC): The translational study on a phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II-III COC patients (PETACC 3-EORTC 40993-SAKK 60/00)